Skip to main content
main-content

Tipp

Weitere Artikel dieser Ausgabe durch Wischen aufrufen

Erschienen in: Notfall + Rettungsmedizin 8/2019

15.10.2018 | Leitthema

Antikoagulanzien und Blutplättchenaggregationshemmer bei Patienten mit akutem Koronarsyndrom

Pro und Kontra

verfasst von: Dr. med. J. Krohn, Prof. Dr. C. A. Gleißner, Prof. Dr. A. Zirlik, Dr. D. L. Staudacher

Erschienen in: Notfall + Rettungsmedizin | Ausgabe 8/2019

Einloggen, um Zugang zu erhalten

Zusammenfassung

Blutverdünnende Medikamente sind ein fester Bestandteil der leitliniengerechten Akuttherapie von Patienten mit akuten Koronarsyndromen. Unter die medikamentöse Therapie fallen sowohl Antikoagulanzien wie auch Blutplättchenaggregationshemmer. Da eine Hemmung der Blutgerinnung notgedrungen mit einer Erhöhung der Blutungsneigung einhergeht und potenziell schwerwiegende Komplikationen bedingen kann, ist die Indikationsstellung der Gabe einer Blutverdünnung komplex. Dieser Beitrag diskutiert anhand einer typischen Patientin mit einem akuten Koronarsyndrom das Für und Wider der Gabe von Antikoagulanzien und Blutplättchenaggregationshemmern im Einklang mit den aktuellen Therapieleitlinien. Eingegangen wird sowohl auf Acetylsalicylsäure, Heparin, P2Y12-Hemmer wie Clopidogrel oder Ticagrelor und die Lysetherapie mit rekombinantem Plasminogenaktivator in einem präklinischen Setting.
Literatur
1.
Zurück zum Zitat Ahrens I, Bode C, Zirlik A (2014) Anticoagulation during and after acute coronary syndrome. Hamostaseologie 34:72–77 CrossRef Ahrens I, Bode C, Zirlik A (2014) Anticoagulation during and after acute coronary syndrome. Hamostaseologie 34:72–77 CrossRef
2.
Zurück zum Zitat Andersen HR, Nielsen TT, Rasmussen K et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742 CrossRef Andersen HR, Nielsen TT, Rasmussen K et al (2003) A comparison of coronary angioplasty with fibrinolytic therapy in acute myocardial infarction. N Engl J Med 349:733–742 CrossRef
3.
Zurück zum Zitat For the Austrian Acute PCII, Dörler J, Edlinger M et al (2011) Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 32:2954–2961 CrossRef For the Austrian Acute PCII, Dörler J, Edlinger M et al (2011) Clopidogrel pre-treatment is associated with reduced in-hospital mortality in primary percutaneous coronary intervention for acute ST-elevation myocardial infarction. Eur Heart J 32:2954–2961 CrossRef
4.
Zurück zum Zitat Ibanez B, James S, Agewall S et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177 CrossRef Ibanez B, James S, Agewall S et al (2017) 2017 ESC Guidelines for the management of acute myocardial infarction in patients presenting with ST-segment elevation: The Task Force for the management of acute myocardial infarction in patients presenting with ST-segment elevation of the European Society of Cardiology (ESC). Eur Heart J 39:119–177 CrossRef
5.
Zurück zum Zitat James S, Åkerblom A, Cannon CP et al (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 157:599–605 CrossRef James S, Åkerblom A, Cannon CP et al (2009) Comparison of ticagrelor, the first reversible oral P2Y12 receptor antagonist, with clopidogrel in patients with acute coronary syndromes: rationale, design, and baseline characteristics of the PLATelet inhibition and patient Outcomes (PLATO) trial. Am Heart J 157:599–605 CrossRef
6.
Zurück zum Zitat Montalescot G, Bolognese L, Dudek D et al (2013) Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369:999–1010 CrossRef Montalescot G, Bolognese L, Dudek D et al (2013) Pretreatment with prasugrel in non-ST-segment elevation acute coronary syndromes. N Engl J Med 369:999–1010 CrossRef
7.
Zurück zum Zitat Montalescot G, Sideris G, Meuleman C et al (2006) A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48:931–938 CrossRef Montalescot G, Sideris G, Meuleman C et al (2006) A randomized comparison of high clopidogrel loading doses in patients with non-ST-segment elevation acute coronary syndromes: the ALBION (Assessment of the Best Loading Dose of Clopidogrel to Blunt Platelet Activation, Inflammation and Ongoing Necrosis) trial. J Am Coll Cardiol 48:931–938 CrossRef
8.
Zurück zum Zitat Montalescot G, Van ’T Hof AW, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–1027 CrossRef Montalescot G, Van ’T Hof AW, Lapostolle F et al (2014) Prehospital ticagrelor in ST-segment elevation myocardial infarction. N Engl J Med 371:1016–1027 CrossRef
9.
Zurück zum Zitat Morrison LJ, Verbeek PR, Mcdonald AC et al (2000) Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 283:2686–2692 CrossRef Morrison LJ, Verbeek PR, Mcdonald AC et al (2000) Mortality and prehospital thrombolysis for acute myocardial infarction: a meta-analysis. JAMA 283:2686–2692 CrossRef
10.
Zurück zum Zitat Rathore SS, Curtis JP, Chen J et al (2009) Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ 338:b1807 CrossRef Rathore SS, Curtis JP, Chen J et al (2009) Association of door-to-balloon time and mortality in patients admitted to hospital with ST elevation myocardial infarction: national cohort study. BMJ 338:b1807 CrossRef
11.
Zurück zum Zitat Roffi M, Patrono C (2016) CardioPulse:“Ten Commandments” of 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS). Eur Heart J 37:208–208 CrossRef Roffi M, Patrono C (2016) CardioPulse:“Ten Commandments” of 2015 European Society of Cardiology Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation (NSTE-ACS). Eur Heart J 37:208–208 CrossRef
12.
Zurück zum Zitat Roffi M, Patrono C, Collet J‑P et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315 CrossRef Roffi M, Patrono C, Collet J‑P et al (2016) 2015 ESC Guidelines for the management of acute coronary syndromes in patients presenting without persistent ST-segment elevation: Task Force for the Management of Acute Coronary Syndromes in Patients Presenting without Persistent ST-Segment Elevation of the European Society of Cardiology (ESC). Eur Heart J 37:267–315 CrossRef
13.
Zurück zum Zitat Schafer A, Bauersachs J (2017) Focused update on dual antiplatelet treatment : ESC guidelines 2017. Herz 42:739–745 CrossRef Schafer A, Bauersachs J (2017) Focused update on dual antiplatelet treatment : ESC guidelines 2017. Herz 42:739–745 CrossRef
14.
Zurück zum Zitat Valgimigli M, Bueno H, Byrne RA et al (2017) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 53:34–78 CrossRef Valgimigli M, Bueno H, Byrne RA et al (2017) 2017 ESC focused update on dual antiplatelet therapy in coronary artery disease developed in collaboration with EACTS. Eur J Cardiothorac Surg 53:34–78 CrossRef
15.
Zurück zum Zitat Van De Werf F, Adgey J, Ardissino D et al (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354:716–722 CrossRef Van De Werf F, Adgey J, Ardissino D et al (1999) Single-bolus tenecteplase compared with front-loaded alteplase in acute myocardial infarction: the ASSENT-2 double-blind randomised trial. Lancet 354:716–722 CrossRef
16.
Zurück zum Zitat Zeymer U, Arntz H‑R, Mark B et al (2012) Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 101:305–312 CrossRef Zeymer U, Arntz H‑R, Mark B et al (2012) Efficacy and safety of a high loading dose of clopidogrel administered prehospitally to improve primary percutaneous coronary intervention in acute myocardial infarction: the randomized CIPAMI trial. Clin Res Cardiol 101:305–312 CrossRef
Metadaten
Titel
Antikoagulanzien und Blutplättchenaggregationshemmer bei Patienten mit akutem Koronarsyndrom
Pro und Kontra
verfasst von
Dr. med. J. Krohn
Prof. Dr. C. A. Gleißner
Prof. Dr. A. Zirlik
Dr. D. L. Staudacher
Publikationsdatum
15.10.2018
Verlag
Springer Medizin
Erschienen in
Notfall + Rettungsmedizin / Ausgabe 8/2019
Print ISSN: 1434-6222
Elektronische ISSN: 1436-0578
DOI
https://doi.org/10.1007/s10049-018-0535-3